The expansion of kinase drug discovery: new targets, platforms and indications.

Kinase drug discovery has expanded into a diverse therapeutic landscape with over 150 regulatory approvals worldwide and more than 2,100 kinase-targeting agents in clinical development.

• Why it matters: The field has diversified beyond ATP-competitive small molecules, but the current landscape, clinical trends, and factors behind success or discontinuation remain to be synthesized.
• What they did: This Review analyzes the kinase therapeutic landscape, covering platforms, targeting approaches, target spectrum, approvals, and trends across 23,000 clinical trials.
• The result: Nearly half of canonical human protein kinases have at least one clinical-stage agent, while development remains concentrated on a small set of blockbuster targets like EGFR.

AI summary of the abstract · may contain errors · not medical advice · read the paper.